P. Peyronnet

729 total citations
20 papers, 408 citations indexed

About

P. Peyronnet is a scholar working on Transplantation, Surgery and Nephrology. According to data from OpenAlex, P. Peyronnet has authored 20 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Transplantation, 6 papers in Surgery and 4 papers in Nephrology. Recurrent topics in P. Peyronnet's work include Renal Transplantation Outcomes and Treatments (7 papers), Pregnancy and Medication Impact (3 papers) and Neurological Complications and Syndromes (2 papers). P. Peyronnet is often cited by papers focused on Renal Transplantation Outcomes and Treatments (7 papers), Pregnancy and Medication Impact (3 papers) and Neurological Complications and Syndromes (2 papers). P. Peyronnet collaborates with scholars based in France, United States and Czechia. P. Peyronnet's co-authors include C. Leroux‐Robert, C Lagarde, Hüseyin Karaaslan, Y. Jacques, Jean‐Paul Soulillou, Maryvonne Hourmant, Brigitte Le Mauff, Yannick Le Meur, M. Hirn and Daniel Olive and has published in prestigious journals such as The Lancet, American Journal of Kidney Diseases and Transplantation.

In The Last Decade

P. Peyronnet

19 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Peyronnet France 11 94 90 87 83 78 20 408
Robert Soberman United States 16 102 1.1× 36 0.4× 54 0.6× 186 2.2× 288 3.7× 47 711
Bernardo Faria Portugal 10 194 2.1× 54 0.6× 126 1.4× 124 1.5× 27 0.3× 23 442
A. Elli Italy 15 121 1.3× 19 0.2× 26 0.3× 141 1.7× 169 2.2× 47 547
D Zaïd Morocco 11 153 1.6× 16 0.2× 85 1.0× 60 0.7× 12 0.2× 48 441
Stanley C. Jordan United States 6 204 2.2× 14 0.2× 88 1.0× 53 0.6× 39 0.5× 8 423
Gagnadoux Mf France 13 201 2.1× 15 0.2× 40 0.5× 80 1.0× 112 1.4× 42 480
Miha Arnol Slovenia 12 115 1.2× 31 0.3× 38 0.4× 100 1.2× 244 3.1× 67 457
J. C. Davin Belgium 14 241 2.6× 15 0.2× 126 1.4× 116 1.4× 14 0.2× 33 454
A. van Es Netherlands 9 25 0.3× 11 0.1× 62 0.7× 34 0.4× 74 0.9× 17 290
Martin Griebel Germany 10 165 1.8× 10 0.1× 49 0.6× 88 1.1× 103 1.3× 12 476

Countries citing papers authored by P. Peyronnet

Since Specialization
Citations

This map shows the geographic impact of P. Peyronnet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Peyronnet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Peyronnet more than expected).

Fields of papers citing papers by P. Peyronnet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Peyronnet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Peyronnet. The network helps show where P. Peyronnet may publish in the future.

Co-authorship network of co-authors of P. Peyronnet

This figure shows the co-authorship network connecting the top 25 collaborators of P. Peyronnet. A scholar is included among the top collaborators of P. Peyronnet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Peyronnet. P. Peyronnet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Venat‐Bouvet, Laurence, Franck Saint‐Marcoux, C Lagarde, et al.. (2007). Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. Anti-Cancer Drugs. 18(8). 977–980. 17 indexed citations
2.
Karaaslan, Hüseyin, et al.. (2001). Risk of heparin lock‐related bleeding when using indwelling venous catheter in haemodialysis. Nephrology Dialysis Transplantation. 16(10). 2072–2074. 81 indexed citations
3.
Ligny, Bruno Hurault de, Olivier Toupance, S. Lavaud, et al.. (2000). FACTORS PREDICTING THE LONG-TERM SUCCESS OF MAINTENANCE CYCLOSPORINE MONOTHERAPY AFTER KIDNEY TRANSPLANTATION1. Transplantation. 69(7). 1327–1332. 7 indexed citations
4.
Peyronnet, P., et al.. (1998). Successful surgical management of a ruptured abdominal aortic aneurysm in a renal transplant patient. A case report.. PubMed. 39(6). 765–7. 11 indexed citations
5.
Meur, Yannick Le, Arnaud Jaccard, Barbara Petit, et al.. (1998). [Lymphoproliferative syndromes after renal transplantation].. PubMed. 19(5). 255–61. 10 indexed citations
6.
Meur, Yannick Le, C. Bédane, P. Clavère, P. Peyronnet, & C. Leroux‐Robert. (1997). A proliferative vascular tumour of the skin in a kidney-transplant recipient (recurrent pyogenic granuloma with satellitosis). Nephrology Dialysis Transplantation. 12(6). 1271–1273. 6 indexed citations
7.
Touchard, Guy, Thierry Hauet, P. Peyronnet, et al.. (1997). Maintenance cyclosporin monotherapy after renal transplantation-clinical predictors of long-term outcome. Nephrology Dialysis Transplantation. 12(9). 1956–1960. 14 indexed citations
8.
Delbosc, B, et al.. (1997). [Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases].. PubMed. 20(7). 507–14. 9 indexed citations
9.
Drouet, M, Barbara Petit, P. Peyronnet, et al.. (1995). Soluble HLA class 1 antigens in kidney allograft recipients.. PubMed. 27(2). 1671–1671. 2 indexed citations
10.
Roger, Douglas J., Jean‐Claude Aldigier, P. Peyronnet, J.-M. Bonnetblanc, & C. Leroux‐Robert. (1993). Acquired ichthyosis and pyoderma gangrenosum in a patient with systemic lupus erythematosus. Clinical and Experimental Dermatology. 18(3). 268–270. 20 indexed citations
11.
Poux, Jean‐Michel, et al.. (1992). Hypokalemic quadriplegia and respiratory arrest revealing primary Sjögren's syndrome.. PubMed. 37(4). 189–91. 56 indexed citations
12.
Lagarde, C, P. Peyronnet, Fabrice Denis, Mohammed Benzakour, & C Leroux-Robert. (1989). <i>Salmonella bonariensis </i>Salmonellosis, Rhabdomyolysis, and Acute Renal Failure. ˜The œNephron journals/Nephron journals. 53(2). 179–180. 10 indexed citations
13.
Cantarovich, Diego, Brigitte Le Mauff, Maryvonne Hourmant, et al.. (1988). Prophylactic Use of a Monoclonal Antibody (33B3.1) Directed Against Interleukin 2 Receptor Following Human Renal Transplantation. American Journal of Kidney Diseases. 11(2). 101–106. 27 indexed citations
14.
Peyronnet, P., Maryvonne Hourmant, Diego Cantarovich, et al.. (1988). Prophylactic treatment of human kidney allograft recipients with a monoclonal antibody (33B3.1) directed against interleukin 2 receptor.. PubMed. 20(2). 300–2. 3 indexed citations
15.
Soulillou, Jean‐Paul, Brigitte Le Mauff, Daniel Olive, et al.. (1987). PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2. The Lancet. 329(8546). 1339–1342. 96 indexed citations
16.
Peyronnet, P., et al.. (1985). Urokinase Infusion for Obstructed Catheters and Peritonitis. Peritoneal Dialysis International. 5(1). 77–77. 14 indexed citations
17.
Peyronnet, P., et al.. (1985). Fungal Peritonitis in Patients on Continuous Ambulatory Peritoneal Dialysis. ˜The œNephron journals/Nephron journals. 41(2). 203–206. 20 indexed citations
18.
Peyronnet, P., et al.. (1985). [Pneumococcal cellulitis in an immunosuppressed patient].. PubMed. 14(25). 1386–1386. 3 indexed citations
19.
Peyronnet, P.. (1976). Le théâtre d'éducation des jésuites. Dix-huitième siècle. 8(1). 107–120. 1 indexed citations
20.
Peyronnet, P.. (1974). La mise en scène au XVIIIe siècle. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Soberman Breakdown of academic impact, for papers by Bernardo Faria Breakdown of academic impact, for papers by A. Elli Breakdown of academic impact, for papers by D Zaïd Breakdown of academic impact, for papers by Stanley C. Jordan Breakdown of academic impact, for papers by Gagnadoux Mf Breakdown of academic impact, for papers by Miha Arnol Breakdown of academic impact, for papers by J. C. Davin Breakdown of academic impact, for papers by A. van Es Breakdown of academic impact, for papers by Martin Griebel
Rankless by CCL
2026